VIDEO: Alpha-emitting radioantibody lowers PSA in castration-resistant prostate cancer

CHICAGO — In this video, Michael J. Morris, MD, FASCO, discusses results of the phase 2 CONVERGE-01 trial evaluating an alpha-emitting radioantibody for patients with metastatic castration-resistant prostate cancer. Treatment effects also included a decline in prostate-specific antigen. Findings from the study, which assessed the safety and efficacy of Ac-225 rosopatamab tetraxetan (CONV01-alpha,